The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: A retrospective study

Expert Opinion on Drug Safety

Volumn 9, Issue 6, 2010, Pages 875-881

  Ricchi, Paolo ^a   Ammirabile, Massimiliano ^a   Costantini, Silvia ^a   Cinque, Patrizia ^a   Lanza, Alfonso Galeota ^a   Spasiano, Anna ^a   Di Matola, Tiziana ^b   Di Costanzo, Giovanni ^a   Pagano, Leonilde ^a   Prossomariti, Luciano ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b Centro Traumatologico Ortopedico ASLNA1   (Italy)

Author keywords

Agranulocytosis; Deferiprone; Interferon; Neutropenia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; PEGINTERFERON ALPHA;

ADULT; AGRANULOCYTOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CELL COUNT; CHELATION THERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; INCIDENCE; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPLENECTOMY; THALASSEMIA MAJOR; THALASSEMIA MINOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGRANULOCYTOSIS; ANTIVIRAL AGENTS; BETA-THALASSEMIA; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NEUTROPENIA; POLYETHYLENE GLYCOLS; PYRIDONES; RETROSPECTIVE STUDIES; SIDEROPHORES;

EID: 77958028069     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.510831     Document Type: Article

References (20)

1. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587
2. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
4. Ricchi P, Ammirabile M, Spasiano A, et al. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. Eur J Haematol 2010;85:36-42
5. Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J 2004;5:475-479
6. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-189
7. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desfoerrioxamine in thalassemia major. Haematologica 2005;90:1163-1168
8. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-3744
9. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884
10. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12
11. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-644
12. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006;85:315-319
13. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009;145:245-254
14. Vlachaki E, Ioannidou-Papagiannaki E, Tziomalos K, et al. Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. Eur J Haematol 2007;78:48-51
15. Durante-Mangoni E, Iardino P, Utili R, et al. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts. Antivir Ther 2006;11:637-640
16. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14:782-787
17. Younossi ZM, Nader FH, Bai C, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008;15:370-378
18. Quintas-Cardama A, De Souza Santos FP, Kantarjian H, et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115:3935-3943
19. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013-1017
20. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 2009;84:428-434